Onyx Biotec Ltd
Incorporated in 2005, Onyx Biotech Ltd manufactures and sells Sterile Water for Injections, Dry Powder Injections and Dry
Syrup for India and overseas, through a
B2B business model[1]
- Market Cap ₹ 87.0 Cr.
- Current Price ₹ 48.0
- High / Low ₹ 97.4 / 48.0
- Stock P/E 17.6
- Book Value ₹ 30.7
- Dividend Yield 0.00 %
- ROCE 13.7 %
- ROE 12.3 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 12.4% over last 3 years.
- Debtor days have increased from 90.2 to 119 days.
- Working capital days have increased from 86.2 days to 121 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 44.86 | 39.49 | 53.75 | 61.95 | |
| 39.09 | 34.99 | 45.42 | 51.60 | |
| Operating Profit | 5.77 | 4.50 | 8.33 | 10.35 |
| OPM % | 12.86% | 11.40% | 15.50% | 16.71% |
| 0.12 | 0.11 | 0.13 | 1.17 | |
| Interest | 0.65 | 0.57 | 2.16 | 1.99 |
| Depreciation | 1.45 | 1.49 | 2.25 | 3.05 |
| Profit before tax | 3.79 | 2.55 | 4.05 | 6.48 |
| Tax % | 11.61% | 27.45% | 25.19% | 23.46% |
| 3.35 | 1.84 | 3.03 | 4.95 | |
| EPS in Rs | 5.68 | 3.12 | 2.27 | 2.73 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 11% |
| TTM: | 15% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 14% |
| TTM: | 63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 12% |
| Last Year: | 12% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 5.90 | 5.90 | 13.32 | 18.13 |
| Reserves | 10.47 | 12.30 | 11.56 | 37.49 |
| 12.25 | 29.23 | 30.78 | 12.46 | |
| 8.22 | 11.30 | 18.47 | 23.17 | |
| Total Liabilities | 36.84 | 58.73 | 74.13 | 91.25 |
| 17.23 | 42.50 | 43.48 | 40.90 | |
| CWIP | 4.02 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| 15.59 | 16.23 | 30.65 | 50.35 | |
| Total Assets | 36.84 | 58.73 | 74.13 | 91.25 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 0.49 | 1.96 | 1.52 | ||
| -5.78 | -22.68 | -3.15 | ||
| 5.20 | 16.43 | 3.09 | ||
| Net Cash Flow | -0.09 | -4.30 | 1.46 |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 68.51 | 46.95 | 104.37 | 119.19 |
| Inventory Days | 41.98 | 109.92 | 92.94 | 150.14 |
| Days Payable | 59.46 | 120.16 | 140.83 | 156.02 |
| Cash Conversion Cycle | 51.03 | 36.71 | 56.48 | 113.32 |
| Working Capital Days | 65.09 | 51.39 | 86.11 | 121.08 |
| ROCE % | 8.23% | 12.05% | 13.69% |
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
28 May 2025 - No deviation in utilization of Rs.25.38 Cr IPO funds as per prospectus till Mar 31, 2025.
-
Outcome of Board Meeting
28 May 2025 - Onyx Biotec reports FY25 audited results; Rs.2538L IPO proceeds utilized as per objectives; profit Rs.495L up from Rs.363L
-
Outcome of Board Meeting
28 May 2025 - Onyx Biotec reports audited FY25 results; Rs. 2538L IPO proceeds utilized as per objectives; profit Rs. 495L.
-
Board Meeting Intimation
23 May 2025 - Onyx Biotec Limited has informed about Board Meeting to be held on 28-May-2025 to inter-alia consider and approve the Audited Financial results of the Company …
-
General Updates
24 April 2025 - Onyx Biotec signs agreement with Galpha Labs for Dry Powder Injection manufacturing.
Annual reports
No data available.
Business Overview:[1]
OBL is associated with the healthcare segment and is a supplier of sterile pharmaceutical products to major corporations. Presently, OBL manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. It provides end-to-end product development and manufacturing solutions and its services
also include preparation and filing of regulatory dossiers in the Indian and global markets.